Aurinia Pharmaceuticals

$13.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.49 (-3.40%) Today
$0.00 (0.00%) As of 5:15 PM EST after-hours

Why Robinhood?

You can buy or sell AUPH and other stocks, options, and ETFs commission-free!

About AUPH

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada. The listed name for AUPH is Aurinia Pharmaceuticals Inc Ordinary Shares.

CEO
Peter S. Greenleaf
Employees
62
Headquarters
Victoria, British Columbia
Founded
1993
Market Cap
1.76B
Price-Earnings Ratio
Dividend Yield
Average Volume
1.45M
High Today
$14.66
Low Today
$13.83
Open Price
$14.64
Volume
1.27M
52 Week High
$21.93
52 Week Low
$5.79

Collections

AUPH Earnings

-$0.29
-$0.19
-$0.10
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
-$0.15 per share
Actual
-$0.28 per share

You May Also Like